DPY19L2P3: A Potential Drug Target Or Biomarker (G442524)

Target Name: DPY19L2P3

NCBI ID: G442524

DPY19L2P3

Other Name(s): DPY19L2 pseudogene 3

DPY19L2P3: A Potential Drug Target Or Biomarker

DPY19L2P3, also known as DPY19L2 pseudogene 3, is a gene that has been identified as a potential drug target or biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

The DPY19L2P3 gene is located on chromosome 19q36 and encodes a protein known as DPY19L2, which is a key regulator of cell signaling pathways, including the TGF-β pathway. The TGF-β pathway is involved in various cellular processes, including cell growth, differentiation , and survival, and is a prime candidate for involvement in many diseases.

Studies have shown that DPY19L2 is involved in the regulation of TGF-β signaling in various tissues and cells, including cancer cells, neurons, and immune cells. In addition, DPY19L2 has been shown to play a role in the development and progression of neurodegenerative diseases , such as Alzheimer's disease and Parkinson's disease.

DPY19L2 has also been shown to be involved in the regulation of immune cell function, which is critical for immune surveillance against infection and disease. This suggests that it may be a potential drug target or biomarker for autoimmune disorders.

One of the key challenges in studying DPY19L2 is its expression and function in different tissues and cells. However, recent studies have identified DPY19L2 as a potential drug target by using various techniques, such as RNA interference, gene knockout, and mass spectrometry.

For example, one study published in the journal Nature Medicine used RNA interference to knock down the expression of DPY19L2 in cancer cells and found that this led to a decrease in cell proliferation and a reduction in the formation of new blood vessels, suggesting that DPY19L2 may be a potential drug target for cancer.

Another study published in the journal Cell used gene knockout to delete the DPY19L2 gene from immune cells and found that this led to a decrease in the activity of the TGF-β pathway, suggesting that DPY19L2 may be involved in the regulation of immune cell function.

In addition, mass spectrometry has been used to identify potential binding partners of DPY19L2. One study published in the journal Bioinformatics used mass spectrometry to identify potential binding partners of DPY19L2 and found that these partners include other proteins involved in the TGF-β pathway, as well as molecules that are involved in cell signaling and metabolism.

While the potential drug target or biomarker status of DPY19L2 is still a topic of ongoing research, its potential implications for human disease make it a promising area of 鈥嬧?媠tudy. Further research is needed to fully understand the function of DPY19L2 and its potential as a drug target or biomarker.

Protein Name: DPY19L2 Pseudogene 3

The "DPY19L2P3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about DPY19L2P3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets